Download PDF
Aktuelle Rheumatologie 2013; 38(01): 45-49
DOI: 10.1055/s-0032-1301928
Übersichtsarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Kardiovaskuläre Risiken der Therapie mit Zyklooxygenasehemmern (NSAR): Biomarker als Risikoindikatoren?

Cardiovascular Risks of Cyclooxygenase Inhibitors (NSAIDs): Biomarkers for Risk Assessment?
K. Brune
1   Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universität Erlangen-Nürnberg, Erlangen
,
F. Ren
2   Harvard Medical School, TIMI Study Group, Brigham and Women’s Hospital, Cardiovascular Division, Boston, United States
,
C. T. Ruff
2   Harvard Medical School, TIMI Study Group, Brigham and Women’s Hospital, Cardiovascular Division, Boston, United States
,
B. Renner
1   Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universität Erlangen-Nürnberg, Erlangen
› Author Affiliations
Further Information

Publication History

Publication Date:
28 February 2012 (online)

Also available at
    Permissions and Reprints

Corrected by:

Kardiovaskuläre Risiken der Therapie mit Zyklooxygenasehemmern (NSAR): Biomarker als Risikoindikatoren?Aktuelle Rheumatologie 2013; 38(01): e1-e1
DOI: 10.1055/s-0033-1343455

Zusammenfassung

Nicht-steroidale Antiphlogistika sind als Schmerzmittel unverzichtbar. Sie stehen wegen unerwünschter Arzneimittelwirkungen (zuletzt: Herz-Kreislauf-Erkrankungen) in der öffentlichen Kritik. Gerade ältere Menschen können ohne diese Wirkstoffe kaum auskommen. Da es an Alternativen mangelt, geht es darum, diejenigen Patienten zu erkennen, die ein besonders hohes kardiovaskuläres Risiko beim Gebrauch dieser Wirkstoffe aufweisen. Wir berichten über Untersuchungen zur Wertigkeit des „Biomarkers“ NTproBNP als Prädiktor für kardiovaskuläre Probleme bei Patienten unter Langzeitbehandlung mit Zyklooxygenasehemmern. Im Gegensatz zum hsCRP zeigt NTproBNP ein erhöhtes Risiko für kardiovaskuläre Probleme zuverlässig an.

Abstract

Non-steroidal, anti-inflammatory drugs (NSAIDs, inhibitors of cyclooxygenases) are still worldwide the most intensively used remedies. These compounds are reliable therapeutics for muscle, joint, back, and traumatic pain. They cause, however, many unwanted side effects. Recently, the propensity of these compounds to cause cardiovascular diseases has been highlighted. As there are no alternatives available, attempts are made to single out those patients who are likely to develop unwanted cardiovascular drug effects when treated with NSAIDs. 2 widely used biomarkers were investigated as predictors of cardiovascular risks aggravated by the treatment with cyclooxygenase inhibitors. We here report on positive results of such evaluations employing the biomarker NTproBNP.

Schlüsselwörter

NSAR - natriuretisches Peptid - C-reaktives Protein - kardiovaskuläres Risiko - Zyklooxygenase-Inhibitoren

Key words

NSAID - natriuretic peptide - C-reactive peptide - cardiovascular risk - cyclooxygenase inhbitors
 

  • Literatur

  • 1 Schwabe U, Paffrath D. Arzneiverordnungs-Report 2011. Springer-Verlag; 2011
    CrossrefGoogle Scholar
  • 2 Brune K, Renner B, Hinz B. Using pharmacokinetic principles to optimize pain therapy. Nat Rev Rheumatol 2010; 6: 589-598
    CrossrefPubMedGoogle Scholar
  • 3 Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15
    CrossrefPubMedGoogle Scholar
  • 4 Grosser T, Yu Y, FitzGerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med 2010; 61: 17-33
    CrossrefPubMedGoogle Scholar
  • 5 Marnett LJ. The COXIB experience: a look in the rearview mirror. Annu Rev Pharmacol Toxicol 2009; 49: 265-290
    CrossrefPubMedGoogle Scholar
  • 6 Solomon DH, Rassen JA, Glynn RJ et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010; 170: 1968-1976
    CrossrefPubMedGoogle Scholar
  • 7 BÄK, KBV, AWMF. Nationale VersorgungsLeitlinie Kreuzschmerz – Langfassung. Version 1.2. 2011. Im Internet http://www.versorgungsleitlinien.de/themen/kreuzschmerz Stand: 08.2011; Zugriff: 20.11.2011
    PubMedGoogle Scholar
  • 8 DGSS. Langzeitanwendung von Opioiden bei nicht tumorbedingten Schmerzen (LONTS). Im Internet http://www.awmf.org/leitlinien/detail/ll/041-003.html Stand: 01.06.2009; Zugriff: 10.01.2012
    PubMedGoogle Scholar
  • 9 Unger SI, Baerwald C. Schmerztherapie mit selektiven und nichtselektiven Cyclooxygenaseinhibitoren in der Rheumatologie. Akt Rheumatol 2010; 35: 178-183
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Januzzi Jr JL. Use of biomarkers to predict cardiac risk from medications: getting to the heart of the matter. Clin Chem 2008; 54: 1107-1109
    CrossrefPubMedGoogle Scholar
  • 11 Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771-1781
    CrossrefPubMedGoogle Scholar
  • 12 Blankfield RP. Can natriuretic peptide levels predict the cardiovascular complications of COX-2 inhibitors and nonsteroidal anti-inflammatory drugs?. J Am Board Fam Med 2006; 19: 178-182
    CrossrefPubMedGoogle Scholar
  • 13 Galvani M, Ottani F, Oltrona L et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004; 110: 128-134
    CrossrefPubMedGoogle Scholar
  • 14 Giannitsis E. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP. Clin Lab 2005; 51: 63-83
    PubMedGoogle Scholar
  • 15 Harney SM, Timperley J, Daly C et al. Brain natriuretic peptide is a potentially useful screening tool for the detection of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 136
    CrossrefPubMedGoogle Scholar
  • 16 Provan S, Angel K, Semb AG et al. NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Ann Rheum Dis 2010; 69: 1946-1950
    CrossrefPubMedGoogle Scholar
  • 17 Solus J, Chung CP, Oeser A et al. Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2662-2669
    CrossrefPubMedGoogle Scholar
  • 18 Kistorp C, Raymond I, Pedersen F et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616
    CrossrefPubMedGoogle Scholar
  • 19 Wong M, Toh L, Wilson A et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003; 48: 81-89
    CrossrefPubMedGoogle Scholar
  • 20 Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-2368
    CrossrefPubMedGoogle Scholar
  • 21 Morrow DA, Cannon CP, Jesse RL et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007; 115: e356-e375
    CrossrefPubMedGoogle Scholar
  • 22 Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 2011; 57: 131-140
    CrossrefPubMedGoogle Scholar
  • 23 Brune K, Furst DE. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?. Rheumatology (Oxford) 2007; 46: 911-919
    CrossrefPubMedGoogle Scholar
  • 24 Häupl T, Burmester GR, Giannitsis E et al. N-terminal prohormone brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with rheumatoid arthritis or osteoarthritis?. Ann Rheum Dis 2007; 66: 838-839
    CrossrefPubMedGoogle Scholar
  • 25 Brune K, Katus HA, Moecks J et al. N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial. Clin Chem 2008; 54: 1149-1157
    CrossrefPubMedGoogle Scholar
  • 26 Ruff CT, Morrow DA, Jarolim P et al. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. J Rheumatol 2011; 38: 1071-1078
    CrossrefPubMedGoogle Scholar
  • 27 Birbara CA, Puopolo AD, Munoz DR et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo-controlled, 3-month trial. J Pain 2003; 4: 307-315
    CrossrefPubMedGoogle Scholar